language
简体中文 English
中
En
Sep. 2012
Formally established
Sep. 2012
Formally established
Jan. 2013
Started commercial operations with six regions across the country
Jan. 2013
Started commercial operations with six regions across the country
May. 2014
Invested 1.5 billion yuan to build Hanhui manufacturing site in Fuyang, Hangzhou City, Zhejiang Province, with international advanced equipment which obtained the national GMP and Pfizer global quality system certification
May. 2014
Invested 1.5 billion yuan to build Hanhui manufacturing site in Fuyang, Hangzhou City, Zhejiang Province, with international advanced equipment which obtained the national GMP and Pfizer global quality system certification
Dec. 2015
Passed the US FDA on-site audit on the manufacturing line of oral drug products
Dec. 2015
Passed the US FDA on-site audit on the manufacturing line of oral drug products
Oct. 2017
Completed manufacturing technology transfer of innovator, Minocycline Hydrochloride Capsules (Meiman), to the Fuyang site
Oct. 2017
Completed manufacturing technology transfer of innovator, Minocycline Hydrochloride Capsules (Meiman), to the Fuyang site
Nov. 2017
Pfizer transferred its equity stake in Hisun-Pfizer Pharmaceuticals to Hillhouse Capital Management, Ltd, and continued the supply and technology transfer of Pfizer-designated products
Nov. 2017
Pfizer transferred its equity stake in Hisun-Pfizer Pharmaceuticals to Hillhouse Capital Management, Ltd, and continued the supply and technology transfer of Pfizer-designated products
Jun. 2018
Changed company name to Hanhui Pharmaceutical Co., Ltd.
Jun. 2018
Changed company name to Hanhui Pharmaceutical Co., Ltd.
Sep. 2019
Rosuvastatin Calcium Tablets and Irbesartan Tablets, were targeted in the centralized volume-based procurement (4 + 7) in the alliance region
Sep. 2019
Rosuvastatin Calcium Tablets and Irbesartan Tablets, were targeted in the centralized volume-based procurement (4 + 7) in the alliance region
Sep. 2020
Won the 2019 Zhejiang Governmental Quality Award
Sep. 2020
Won the 2019 Zhejiang Governmental Quality Award
Feb. 2021
Hisun acquired the remaining stake in Hanhui Pharmaceuticals Co., Ltd from Hillhouse Capital Management, Ltd, making Hanhui the 100% subsidiary of Hisun Pharmaceutical Co., Ltd
Feb. 2021
Hisun acquired the remaining stake in Hanhui Pharmaceuticals Co., Ltd from Hillhouse Capital Management, Ltd, making Hanhui the 100% subsidiary of Hisun Pharmaceutical Co., Ltd
Jan. 2022
Completed manufacturing technology transfer of innovator, Piperacillin Sodium and Tazobactam Sodium for injection (Tazocin), and put into production formally in the Fuyang site; finished the switch on the national bidding platform
Jan. 2022
Completed manufacturing technology transfer of innovator, Piperacillin Sodium and Tazobactam Sodium for injection (Tazocin), and put into production formally in the Fuyang site; finished the switch on the national bidding platform
Quick Navigator
Contact Us
Hanhui Pharmaceuticals Co., Ltd © HANHUI 2020 All Rights Reserved
Hanhui Pharmaceuticals Co., Ltd © HANHUI 2020 All Rights Reserved